Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

被引：2
|
作者：
Jurczak, Wojciech [1 ]
Zinzani, Pier Luigi [2 ]
Gaidano, Gianluca [3 ]
Goy, Andre [4 ]
Provencio, Mariano [5 ]
Nagy, Zsolt [6 ]
Robak, Tadeusz [7 ]
Maddocks, Kami J. [8 ]
Buske, Christian [9 ]
Ambarkhane, Sumeet [10 ]
Winderlich, Mark [10 ]
Dirnberger-Hertweck, Maren [10 ]
Endell, Jan [10 ]
Blum, Kristie A. [8 ]
机构：
[1] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[2] Univ Bologna, Inst Hematol, Bologna, Italy
[3] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy
[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Univ Hosp Puerta Hierro, Dept Med Oncol, Madrid, Spain
[6] Semmelweis Univ, First Dept Internal Med, Budapest, Hungary
[7] Med Univ Lodz, Dept Hematol, Lodz, Poland
[8] Ohio State Univ Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Columbus, OH USA
[9] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany
[10] MorphoSys AG, Martinsried, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.623.623
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
623
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Stephenson, JJ
    Bartlett, NL
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Hillson, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
  • [22] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
    Bartlett, NL
    Gribben, JC
    Boccia, RV
    Milder, MS
    Aboulafia, DM
    Castro, J
    Flinn, I
    Hayes-Lattin, B
    Kaplan, L
    Lin, T
    Lucas, JB
    Maloney, DG
    McLaughlin, P
    McSweeney, PA
    Mohrbacher, A
    Redfern, C
    Steis, R
    Stephenson, JJ
    Strair, R
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 244B - 244B
  • [23] Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study
    Kamdar, Manali
    Augustson, Bradley
    Rok, Young
    Edwards, James
    Hertzberg, Mark
    Johnston, Amanda
    Kim, Jin Seok
    Kroschinsky, Frank P.
    Smith, Sonali M.
    Stevens, Don A.
    Monnet, Annabelle
    Zhao, Ye
    Nouet, Yann
    Marinova, Viktoriya
    BLOOD, 2020, 136
  • [24] Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Rudersdorf, Nikita
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Jianning
    Zhu, Ming
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Arnason, Jon E.
    Lunning, Matthew Alexander
    Solomon, Scott R.
    Farazi, Thalia
    Garcia, Jacob
    Xie, Benhuai
    Newhall, Kathryn J.
    Dehner, Christine
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
    Bender, Brendan C.
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael C.
    Chanu, Pascal
    BLOOD, 2023, 142
  • [27] Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Dull, Johannes
    Maddocks, Kami J.
    Gonzalez-Barca, Eva
    Jurczak, Wojciech
    Liberati, Anna Marina
    Obr, Ales
    Gaidano, Gianluca
    Abrisqueta, Pau
    Andre, Marc
    Dreyling, Martin H.
    Menne, Tobias
    Dirnberger-Hertweck, Maren
    Weirather, Johannes
    Ambarkhane, Sumeet Vijay
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY
    Klisovic, R.
    Winderlich, M.
    Ambarkhane, S.
    Jabbour, E.
    HAEMATOLOGICA, 2017, 102 : 346 - 346
  • [29] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
  • [30] Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin's lymphoma (DLBCL): A review of the literature
    Slawsky, K. A.
    Goss, T. F.
    Shinkle, R.
    Xu, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345